STA
ALDR

Summit Trail Advisors’s Alder Biopharmaceuticals ALDR Stock Holding History

Summit Trail Advisors’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,961
Closed -$43K – 1995
2017
Q4 		$43K Buy
+2,961
New +$33.1K 0.01% 854

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Summit Trail Advisors's ALDR Position: Q1 2018 in Review

Summit Trail Advisors sold out of Alder Biopharmaceuticals (ALDR) in Q1 2018, closing a stake of 2,961 shares — an estimated $43K sold.

Summit Trail Advisors first reported a position in ALDR in Q4 2017 and held it in 1 quarter. The position peaked at $43K in Q4 2017. 135 funds tracked by Wall St. Rank hold ALDR as of Q1 2018.

  • Summit Trail Advisors reported no remaining Alder Biopharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 2,961 Alder Biopharmaceuticals shares in Q1 2018, an estimated $43K.
  • Summit Trail Advisors first reported a position in Alder Biopharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Alder Biopharmaceuticals position peaked at $43K in Q4 2017.
  • 135 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.